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Introduction
The efficacy of 3-hydroxy-3-methylglutaryl-coenzyme A 
reductase inhibitor (statin) in reducing cardiovascular events 
has been established in many large-scaled randomized con-
trolled trials.
1)2) In addition to their potent effects on choleste-
rol levels, statins influence several other pathways, including 
the inflammatory, oxidative, and thrombotic processes.
3-5)
The inflammatory processes are not only involved in the pa-
thogenesis of atherosclerosis but also in the cause of acute co-
ronary syndromes.
6)7) High levels of C-reactive protein (CRP), 
a prototype inflammatory marker, are associated with incr-
eased cardiovascular disease risks.
8)9)
Many studies have shown that statins reduce CRP levels.
10)11) 
However, it is unclear whether the anti-inflammatory effect 
of statin is mediated by cholesterol reduction per se, or throu-
gh direct mechanisms, the so called pleiotropic effects, as pre-
vious generations of lipid lowering drugs did not have com-
parable potency that of the statins.
A new drug, ezetimibe, inhibits the intestinal absorption 
of cholesterol by impeding cholesterol transport across the 
intestinal wall, and lowers cholesterol levels by over 15%.
12-15) 
Ezetimibe alone does not reduce CRP levels. However, sev-
eral reports have suggested that ezetimibe might potentiate 
the effect of statin on CRP level when administered togeth-
er.
14)15) A study reported that the addition of ezetimibe to pa-
tients taking statins decreased CRP levels.
16) In contrast, sev-
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eral reports have suggested that cholesterol reduction by ez-
etimibe failed to demonstrate the pleiotropic effects of st-
atins.
17-19)
The aim of this study was to investigate the effect of ezetimi-
be on CRP levels when administered to hypercholesterolemic 
patients already receiving statins, and to evaluate the rela-
tionship between the cholesterol reduction and anti-inflam-
matory effects.
Subjects and Methods 
One hundred-seventy and nine (n=179) hypercholesterol-
emic patients were enrolled. The exclusion criteria were: 1) 
new onset diseases that potentially impact on lipid levels, such 
as diabetes mellitus, infectious diseases, or other endocrino-
logic diseases, within 3 months, 2) aspartate aminotransfer-
ase (AST) or alanine aminotransferase (ALT) levels  ≥3-fold 
the upper normal limit, 3) administration of medications wi-
thin the last 3 months that might affect lipid levels, and 4) 
baseline CRP levels ≥10 mg/L. One hundred-twenty (n=120) 
hypercholesterolemic patients receiving statins required ad-
ditional reduction of low density lipoprotein-cholesterol (LDL-
C) to meet the target levels of the National Cholesterol Edu-
cation Program were divided into two groups, the ezetimibe 
group (10 mg of ezetimibe, n=60) and the control group 
(n=60).
20) A patient in the ezetimibe group was excluded in 
the analysis, because follow-up CRP level was over 10 mg/L. 
A third group of hypercholesterolemic patients with similar 
baseline CRP levels and without statin therapy was enrolled 
and treated with statin (statin group, n=59).
CRP and lipid levels were measured before and after man-
agement for 2 months. After overnight fasting, blood samples 
were obtained. Concentrations of total cholesterol and trigly-
ceride were determined by the enzymatic method using an 
automatic analyzer (Model 7150, Hitachi, Japan). LDL-C was 
calculated by the Friedewald equation. The concentration of 
high density lipoprotein-cholesterol (HDL-C) was measured by 
the direct method using immunoinhibition (Wako, Japan). 
The concentration of CRP was determined by the nephelo-
meter method using an N High Sensitivity CRP kit (Dade 
Behring Marburg GmbH, Germany). Interassay coefficients 
of variation were 7.0% and 5.2% for the controls, with levels of 
1.43 mg/dL and 1.74 mg/dL, respectively. The intra-assay co-
efficient of variation was 1.5-3.0%. 
Statistical analysis
Data are expressed as mean±SD. Statistical analysis was 
performed using the Social Package for the Social Sciences 
(SPSS Inc., Chicago, IL, USA). For CRP, lipoprotein (a) and 
triglyceride, the Wilcoxon signed-rank test was used to com-
pare concentrations before and after therapy, and the Mann-
Whitney U test was used to evaluate differences between gr-
oups. For other variables, a paired t-test was used to compare 
concentrations before and after therapy, and the Student t-test 
was used to evaluate differences between groups. Relationships 
between the parameters were analyzed by the Spearman cor-
relation method. The distribution of discrete variables was an-
alyzed using the χ2 test. A two-tailed p<0.05 was considered st-
atistically significant.
Results
Baseline demographic and clinical characteristics were simi-
lar between the ezetimibe group and the control group (Table 
1), except the number of patients with ischemic heart diseases 
(p=0.026). There were no differences in baseline lipid profiles 
and CRP levels between the ezetimibe group and the control 
group (Table 2). CRP levels were similar between the ezeti-
mibe and the statin groups. However, LDL-C levels were hi-
gher in the statin group than in the ezetimibe group, due to 
different inclusion criteria (138.5±21.2 mg/dL vs. 172.9±28.4 
mg/dL, p=0.000) (Table 2). 
Ezetimibe decreased cholesterol and LDL-C levels by 20.2% 
(from 228.1±31.1 mg/dL to 182.1±25.6 mg/dL, p=0.000) and 
28.1% (from 138.5±21.2 mg/dL to 99.6±20.0 mg/dL, p= 
0.000), respectively (Table 2). However, ezetimibe did not 
reduce CRP levels (from 0.83±0.68 mg/L to 1.14±1.21 mg/L, 
p=0.11). CRP levels did not change in the control group (p= 
0.42). 
Changes in CRP levels were not associated with changes 
in LDL-C in the control (r=0.14, p=0.31), the ezetimibe (r= 
0.03, p=0.85), the control+ezetimibe (r=-0.02, p=0.87), and 
the statin groups (r=0.09, p=0.50) (Table 3). Changes in CRP 
levels were negatively associated with baseline CRP levels in 
the control+ezetimibe (r=-0.38, p=0.000) (Fig. 1), the control 
(r=-0.55, p=0.000), and the statin groups (r=-0.60, p=0.000), 
and in the ezetimibe group with borderline significance (r= 
-0.22, p=0.09). In the ezetimibe group, changes in CRP levels 
were negatively related to baseline HDL-C levels (r=-0.35, p= 
0.007). During the follow-up period, a patient in the ezeti-
mibe group experienced elevation of AST and ALT ≥3-fold 
the upper normal limit. No patient experienced elevation of 
creatine kinase ≥10-fold the upper normal limit. 
Discussion
This case-controlled study demonstrated that ezetimibe, a 
new cholesterol lowering drug, failed to decrease CRP levels 
in patients already taking statins, despite marked reduction in 
cholesterol and LDL-C levels. This finding suggests that cho-
lesterol reduction itself does not modify the inflammatory pro-
cesses, and that the anti-inflammatory effects of statins may 
not be secondary to lipid-lowering effect, but due to other 
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The present study had lower baseline CRP levels (0.82-0.84 
mg/L) than previous studies (more than 2 mg/L).
14-16) In the pre-
sent study, changes in CRP levels were associated with base-
line CRP levels. High baseline CRP levels predicted the de-
crease of CRP levels during the follow-up period. This finding 
is consistent with that of previous studies.
21) Therefore, the dif-
ference in baseline CRP levels may explain the discrepancy 
between the present study and previous studies.
To exclude the effect of low baseline CRP levels, a third gr-
oup of patients with similar CRP levels and without statin th-
erapy were included. In these patients, statin lowered CRP 
levels. Therefore, lower baseline CRP levels alone cannot expl-
ain the difference between the present study and previous ones.
Ezetimibe did not reduce CRP levels.
14)15) Several studies 
have suggested that the combined therapy of statin and ezet-
imibe may decrease CRP levels more so than statin monothera-
py.
14)15) However, as the primary aims of most previous stud-
ies focused on the drug’s efficacy on lipid and safety, baseline 
Table 1. Comparison of patient baseline clinical characteristics
Ongoing statin therapy
p
New statin therapy
(n=59) Control (n=60) Ezetimibe (n=59)
Sex (M/F) 16/44 15/44 1000. 24/35
Age 0057.8±10.1 0059.7±11.9 0.340 057.9±11.7 
Height (cm) 159.0±6.5 159.7±8.5 0.620 160.5±8.80
Weight (kg) 065.2±9.9 064.3±9.3 0.640 064.8±12.5
Associated disease, n (%)
Hypertension 40 (66.7) 37 (62.7) 0.700 46 (78)
IHD 5 (8.3) 14 (23.7) 0.026 08 (13.6)
DM  2 (3.3) 1 (1.7) 1000. 03 (5.1)
Medication, n (%)
Atorvastatin 25 (41.7) 18 (30.5) 0.110 59 (100)
Lovastatin 25 (41.7) 21 (35.6)
Pitavastatin 08 (13.3) 12 (20.3)
Simvastatin 2 (3.3) 08 (13.6)
Alcohol, n (%) 07 (11.7) 06 (10.2) 1000. 13 (22.0)
Smoking, n (%) 07 (11.7) 06 (10.2) 1000. 05 (8.5)
IHD: ischemic heart disease, DM: diabetes mellitus
Table 2. Changes in CRP, lipid and lipoprotein profiles
Ongoing statin therapy
p
New statin therapy
(n=59) Control (n=60) Ezetimibe (n=59)
Pre 00.84±0.76 00.83±0.68 0.820 00.82±0.73
CRP(mg/L) Post 00.90±0.94 01.14±1.21 0.550 00.65±0.57
p   0.420 0.110 0.008 
Pre 221.7±30.9 228.1±31.1 0.270 256.8±27.2
Cholesterol (mg/dL) Post 212.3±30.1 182.1±25.6 0.000 181.2±24.5
p   0.002 0.000 0.000
Pre 056.0±13.1 056.8±10.4 0.720 55.1±9.5
HDL-C (mg/dL) Post  055.3±12.8 055.8±11.3 0.810 054.1±10.3
p   0.420 0.250 0.290
Pre  130.0±28.3 138.5±21.2 0.090 172.9±28.4
LDL-C (mg/dL)* Post 123.7±26.5 099.6±20.0 0.000 101.8±22.6
p   0.028 0.000 0.000
Pre 174.3±86.0 153.3±66.8 0.410 149.1±86.8
Triglyceride (mg/dL) Post 165.7±82.4 126.3±54.2 0.003 128.2±58.0
p  0.300 0.000 0.030
Mean±SD. *Calculated by Friedewald equation in cases with triglyceride levels <400 mg/dL. CRP: C-reactive protein, HDL-C: high density 
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CRP levels were different between the groups. In a study wh-
ich evaluated the effect on CRP levels, baseline CRP levels were 
different by 12%.
15) In the present study, baseline CRP levels 
were similar between the control and the ezetimibe groups. 
The efficacy of the co-administration of ezetimibe on CRP 
levels may be different with the types or the dosage of statins. 
In general, the addition of ezetimibe to simvastatin (14.3-
16.6%) was more effective than the addition of ezetimibe to 
atorvastatin (-0.3-10%).
14)15)22-24) The addition of ezetimibe de-
creased CRP levels only in higher dose of statin in some stud-
ies
14) or only in lower dose in other studies.
22) 
In a study which compared the effects on CRP between at-
orvastatin and simvastatin+ezetimibe, combined therapy fa-
iled to provide incremental reduction of CRP levels in spite 
of further reduction of LDL-C by 8.1%.
22) Therefore, it is un-
clear whether co-administration of ezetimibe with statin po-
tentiates the CRP lowering effect of statins.
There are two studies that assessed the effect of ezetimibe 
on CRP levels in patients already taking statins.
16)25) In one st-
udy, addition of ezetimibe decreased CRP levels. However, 
baseline CRP levels were different by 23.5%.
16) That study 
enrolled hypercholesterolemic patients having taken statins 
for 6 weeks and more.
16) In the present study, almost all patients 
were taking statins over 12 months. In the JUPITER study, ro-
suvastatin in patients with elevated CRP levels reduced CRP 
levels from 4.2 mg/L to 2.2 mg/L after 12 months, and reduc-
ed further to 1.8 mg/L after 24 months.
26) Therefore, difference 
in the duration of statin therapy may explain the discrepancy 
between these two studies. It is possible that the addition of 
ezetimibe to statin simultaneously or sequentially facilitate 
reduction of CRP levels without further reduction compared 
with the long-term statin therapy. Lower baseline CRP in the 
present study may partially be explained by the effects of 
long-term statin therapy.
In another study, the addition of ezetimibe to patients tak-
ing statins decreased CRP levels in Caucasian patients but not 
in African and Hispanic patients, although the difference 
did not reach statistical significance. As such, there is a possi-
bility of ethnic difference.
25)27) Recently, pooled data includ-
ing the above two studies
16)25) showed that addition of ezeti-
mibe to patients taking statins decreased CRP levels.
28) 
Statins reduce cardiovascular events not only in hypercho-
lesterolemic patients, but also in high-risk patients with nor-
mal or low cholesterol levels.
1)2) It has been suggested that 
the cardioprotective effects of statins are mediated both by 
their potent effects on cholesterol levels and by other pathways, 
such as the inflammatory, oxidative, and thrombotic process-
es.
3-5) Almost all reports have demonstrated that statins re-
duce CRP levels.
10)11)
However, It is not known whether the pleiotropic effects 
of statins are mediated by cholesterol reduction per se, or by 
other mechanisms. It is because old cholesterol lowering 
drugs are not as potent as statins in reducing cholesterol lev-
Table 3. Relation of changes in CRP levels with baseline lipid levels and their changes
Control group Ezetimibe group Control+Ezetimibe group Statin group
r p r p r p r p
Baseline
CRP -0.55 0.000 -0.22 0.09 -0.38 0.000 -0.60 0.000
Cholesterol -0.00 0.99 -0.15 0.24 -0.06 0.53 -0.10 0.48
HDL-C 0.17 0.18 -0.35 0.007 -0.06 0.50 -0.04 0.80
LDL-C -0.07 0.61 -0.02 0.91 -0.02 0.82 -0.08 0.57
Triglyceride 0.06 0.66 0.19 0.14 0.10 0.28 -0.07 0.61
Changes in 
Cholesterol 0.03 0.82 -0.07 0.59 -0.10 0.29 -0.11 0.43
HDL-C -0.24 0.063 -0.09 0.49 -0.17 0.064 -0.13 0.32
LDL-C 0.14 0.31 0.03 0.85 -0.02 0.87 -0.09 0.50
Triglyceride -0.07 0.58 -0.04 0.76 -0.07 0.45 -0.11 0.43
Mean±SD. CRP: C-reactive protein, HDL-C: high density lipoprotein-cholesterol, LDL-C: low density lipoprotein-cholesterol
Fig. 1. The relation between baseline CRP levels and changes in 
CRP levels in the control and the ezetimibe groups. CRP: C-reac-
tive protein. 
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els. Ezetimibe lowers LDL-C by 16.9-18.7%.
12-16) Its potency 
exceeds that of old cholesterol lowering drugs and is equiva-
lent to earlier statins, lovastatin or pravastatin. These statins 
also lower CRP levels.
10)11)
In the present study, ezetimibe did not decrease CRP lev-
els in patients taking statins in spite of marked lowering of 
LDL-C levels by 28.1%. In addition, changes in CRP levels 
were not related to changes in LDL-C levels in all groups. 
This finding indicates that the anti-inflammatory effect of 
statin may not be secondary to cholesterol reduction.
Several studies have compared the effects on the pleiotro-
pic mechanisms of cholesterol-reduction by ezetimibe with 
that by statins. Cholesterol reduction by ezetimibe, either as 
monotherapy or in addition to statins, failed to improve en-
dothelial vasodilator function reduce platelet reactivity, oxi-
dative stress, and inflammatory parameters.
17-19) These find-
ings are consistent with the results of the present study. 
Recently published studies are also consistent with the pres-
ent study.
29)30)
In the present study, changes in CRP levels were mainly 
associated with baseline CRP levels, and this finding is con-
sistent with previous reports.
21) In the ezetimibe group, CRP 
levels decreased in patients with lower baseline HDL-C lev-
els and increased in those with higher baseline HDL-C lev-
els (r=-0.35, p=0.007). In the control group, changes in CRP 
levels were negatively related to those in HDL-C levels with 
borderline significance (r=-0.24, p=0.063). This may have 
occurred as the inflammation processes decrease HDL-C 
levels. 
This study has several limitations. The number of patients 
is smaller than that in previous studies. However, baseline 
CRP levels were well balanced in contrast to previous stud-
ies. As described above, lower baseline CRP levels may ac-
count for the difference between the outcomes of the present 
study and that of previous studies. This study was performed 
in a single hospital in Asia. The effect of ezetimibe may be 
variable between ethnic populations. Ischemic heart disease 
was more frequent in the ezetimibe group than in the con-
trol group, and this difference may influence the results. 
In summary, ezetimibe failed to decrease CRP levels in 
patients taking statins in spite of marked reduction of total 
and LDL-C levels. Changes in CRP levels were not associat-
ed with that of LDL-C at all. Therefore, cholesterol reduction 
itself may not be able to reduce inflammatory processes in 
patients taking statins.
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